Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on neuroscience and oncology, headquartered in Dublin with operations in North America and Europe. The company researches, develops, and commercializes therapies for sleep disorders, epilepsy, and hematologic and solid tumor cancers.
Its portfolio includes oxybate therapies—Xywav (for narcolepsy and idiopathic hypersomnia) and Xyrem (for narcolepsy); Epidiolex (cannabidiol) for rare epilepsies; Rylaze (recombinant asparaginase) for acute lymphoblastic leukemia; Vyxeos (daunorubicin and cytarabine liposome) for certain high-risk acute myeloid leukemia; Zepzelca (lurbinectedin) for small cell lung cancer; and Defitelio (defibrotide) for hepatic veno-occlusive disease. Jazz advances small molecules, biologics, and cannabinoid-based medicines through internal R&D and partnerships, and expanded its neuroscience capabilities with the 2021 acquisition of GW Pharmaceuticals. The company is listed on Nasdaq under the ticker JAZZ.
